Fenofibrate

證據等級: L5

預測適應症: 7 個

Using the evidence pack as provided (drug info, UK regulatory record, predicted indications with clinical trial/literature evidence). This is a direct content-generation task per the report template already specified in the prompt — no additional skill invocation needed (no coding, no external state to verify beyond what’s in the JSON).

A few data-quality notes before the report: the taiwan_regulatory block shows 0 UK marketing authorisations (fenofibrate not currently licensed in this dataset), original_moa and all safety fields are flagged [Data Gap], and the single clinical trial retrieved for the top-ranked indication (NCT03510715) tests alirocumab, not fenofibrate — I’ve flagged this honestly in the trial table rather than overstating the evidence.

Fenofibrate: From Dyslipidaemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Fenofibrate is a fibrate-class lipid-regulating agent whose established use is in dyslipidaemia and mixed hyperlipidaemia. The TxGNN model predicts it may also be effective for Homozygous Familial Hypercholesterolemia (HoFH), a rare and severe inherited form of hypercholesterolaemia, with 1 clinical trial and 11 publications currently linked to this indication — though only a small subset of that literature provides fenofibrate-specific evidence in HoFH patients.

Quick Overview

Item	Content
Original Indication	Not recorded in this dataset (no UK marketing authorisation on file); literature within the evidence pack describes fenofibrate as a fibrate-class agent for dyslipidaemia/mixed hyperlipidaemia
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.91%
Evidence Level	L3 (observational/case-level clinical data; no fenofibrate-specific RCT identified)
UK Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the drug-level record (original_moa is a data gap). Based on the supporting literature retrieved for this candidate, fenofibrate is a fibric acid derivative and PPAR-alpha (peroxisome proliferator-activated receptor alpha) agonist (PMID 2226216; PMID 20332533). PPAR-alpha activation upregulates lipoprotein lipase and apolipoprotein genes, lowering plasma triglycerides and raising HDL-cholesterol, with a more modest effect on LDL-cholesterol.

Dyslipidaemia/mixed hyperlipidaemia and HoFH sit on the same clinical spectrum — both are disorders of lipoprotein metabolism — but they differ substantially in mechanism and severity. HoFH results from biallelic loss-of-function mutations in the LDL receptor (or related) pathway, producing very high LDL-C from birth and a markedly elevated risk of premature cardiovascular disease. Standard HoFH management (statins, PCSK9 inhibitors, lomitapide, LDL apheresis) targets LDL-receptor-dependent or receptor-independent LDL clearance directly, whereas fenofibrate’s principal benefit is on triglycerides and HDL rather than LDL-receptor function.

Mechanistically, fenofibrate could plausibly serve as an adjunct in HoFH to address residual hypertriglyceridaemia and low HDL-C, rather than as primary LDL-lowering therapy. This is supported by one older case-level observation: in a small fenofibrate study of type II hyperlipoproteinaemia, “one patient with homozygous familial hypercholesterolemia showed the greatest fall of total and LDL cholesterol” among the cohort (PMID 6593751). This is a single, uncontrolled observation from 1984 and should not be read as robust efficacy evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT03510715	Phase 3	Completed	18	Evaluated alirocumab (a PCSK9 inhibitor), not fenofibrate, in children/adolescents (8–17y) with HoFH on background lipid-lowering therapy. Retrieved as the only disease-matched trial in this dataset; it does not constitute direct trial evidence for fenofibrate in HoFH and should be treated as contextual/background-therapy information only.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6593751	1984	Clinical study (case-level)	Pharmacological Research Communications	Fenofibrate 300 mg/day in type II hyperlipoproteinaemia (n=22); one HoFH patient showed the greatest fall in total and LDL cholesterol in the cohort — the only direct fenofibrate-in-HoFH data point identified
24734312	2014	Pharmacokinetic study	Pharmacotherapy	Characterised PK interactions of lomitapide (an approved HoFH adjunct therapy) with commonly co-administered lipid drugs including fenofibrate
24946816	2014	Case report/review	Internal Medicine Journal	Discusses liver transplantation for HoFH and notes emerging lipid-lowering drug treatments as alternatives to LDL apheresis
37979722	2024	Review	Indian Heart Journal	Positions fenofibrate monotherapy as indicated mainly for severe hypertriglyceridaemia (>500 mg/dL) with modest cardiovascular benefit, in the broader context of non-statin lipid drugs
2042836	1991	Review	Annals of the New York Academy of Sciences	Reviews pharmacologic/surgical treatment of dyslipidaemic children, listing fenofibrate among agents used in familial hypercholesterolaemia
28437620	2017	Guideline	Endocrine Practice	AACE/ACE dyslipidaemia and cardiovascular prevention guideline; general lipid-management framework, not HoFH-specific
35499807	2022	Review	Current Atherosclerosis Reports	Reviews dyslipidaemia management in pregnancy; general context only, not HoFH-specific
26432726	2015	Review	Indian Heart Journal	Reviews LDL-C lowering with statins and PCSK9 inhibitors; fenofibrate not a focus
14620392	2003	Review	Pharmacotherapy	Reviews ezetimibe as a cholesterol-absorption inhibitor; comparator drug class context only
9129869	1997	Review	Drugs	Reviews atorvastatin pharmacology; comparator drug class context only

UK Market Information

Fenofibrate does not currently hold a UK marketing authorisation in this dataset (market_status: Not marketed, 0 authorisations on record). No product name, dosage form, or licensed indication text is available to tabulate.

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Note: key_warnings, contraindications, and drug–drug interaction data are all recorded as data gaps in this evidence pack and could not be retrieved (see “To proceed” below).

Conclusion and Next Steps

Decision: Hold

Rationale:

A Blocking data gap (DG001 — missing SmPC warnings/contraindications) prevents any initial safety assessment (S1 stage) for this candidate.
Fenofibrate has no current UK marketing authorisation in this dataset, so a clinical-use pathway would need to be established before any repurposing could proceed.
The only clinical trial retrieved for HoFH evaluates a different drug (alirocumab); direct clinical evidence of fenofibrate specifically in HoFH is limited to a single 1984 case-level observation and supporting mechanistic/PK literature — insufficient to support progression on efficacy grounds alone.

To proceed, the following is needed:

Retrieve TFDA/MHRA SmPC warnings and contraindications (DG001, Blocking)
Confirm mechanism of action via DrugBank API query (DG002)
Clarify UK licensing status/pathway, given 0 current marketing authorisations
Re-verify whether NCT03510715 involves fenofibrate as a concomitant/background therapy, or should be excluded as a non-relevant match
Given standard HoFH care already centres on LDL-receptor-targeted therapies (statins, PCSK9 inhibitors, lomitapide, apheresis), clarify fenofibrate’s intended clinical positioning as adjunct triglyceride/HDL therapy rather than primary LDL-lowering treatment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.